Perrigo Company plc Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Oct-2026Ownership Structure
Ownership Analysis
No single investor controls Perrigo Company plc, and we think that helps shareholders more often than it hurts them. BlackRock owns 16.40% of the 138.8 million ordinary shares, a position it disclosed again in a September 2026 filing and the largest anyone holds. Neuberger Berman Investment Advisers owns 7.70%, Vanguard Group 6.52%, State Street Investment Management 6.15% and Fuller & Thaler Asset Management 5.40%. Outside tabulations put professional investors at close to 99% of the shares, with company insiders owning below 0.5%. The argument against this arrangement, and we take it seriously, is that index funds buy shares because a benchmark tells them to, so they offer no patience when results go wrong. Results have gone wrong. At June 27, 2026 Perrigo carried $3,283.4 million of noncurrent long-term debt against $2,515.8 million of shareholders' equity, and it lost $324.1 million in the first six months. It wrote down $331.8 million more across the Infant Formula, Women's Health and Oral Care reporting units, on top of the $1.3 billion goodwill writedown taken in fiscal 2025. We think June 2026 settles the argument the other way. Orlando D. Ashford's board accepted Patrick Lockwood-Taylor's resignation over conduct that broke the company's code, and it installed Albert Manzone as interim president and chief executive within days. No founder and no private equity sponsor had to be persuaded first. We also think these owners suit a balance sheet repair job, because value managers such as Fuller & Thaler and Thompson, Siegel & Walmsley will hold management to its stated target of cutting net debt to 4.0 times adjusted EBITDA. The April 30, 2026 Dermacosmetics sale sent $362.9 million of net proceeds mostly toward paying debt down. Our concern is the cost of the same arrangement. With the shares near $14.26 and the whole company worth $1.98 billion, no large holder has either the votes or the reason to fight off a cheap takeover bid, and we would expect a serious offer to succeed.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Professional investors own close to 99% of Perrigo's shares, and how that 99% divides tells us more than the total does. BlackRock at 16.40%, Vanguard Group at 6.52%, State Street Investment Management at 6.15%, Geode Capital Management at 2.61% and Norges Bank Investment Management at 1.61% run index funds or something close to them. Their stakes reflect Perrigo's weight in a market index, not a view on the company. The actively managed funds are the ones making a choice. They are Neuberger Berman Investment Advisers at 7.70%, Fuller & Thaler Asset Management at 5.40% and Invesco Capital Management at 4.12%, along with Dimensional Fund Advisors at 3.94%, Thompson, Siegel & Walmsley at 2.39% and GAMCO Investors at 1.61%. Fuller & Thaler buys shares it believes investors have oversold on bad news, and GAMCO has long specialised in companies likely to be bought or broken up. We read that combination as a bet on recovery with a sale as the fallback, not as money settling in for a decade. The dividend points the same way. A $1.16 annual payout on a $14.26 share price is a yield of 8.14%, and we take a yield that high as a sign investors doubt the payout will last. Fiscal 2025 produced a reported diluted loss of $10.12 a share and adjusted earnings of $2.75. Insiders own under 0.5%. We would want a permanent chief executive with his own money in the shares before calling management's interests aligned with ours. Five analysts rate the shares a buy with an average target of $16.50, implying modest gains. We think the range of outcomes is wider than that target suggests, because $1.98 billion of equity sits above $3.3 billion of debt and the strategic reviews of Infant Formula and Oral Care decide most of what happens next. Sales near the values carried on the books would lift the shares quickly. Further writedowns would hit hard, because index funds do not buy more on weakness and these active holders are sized for a trade.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Self Care | Operating Segment | Largest reporting segment covering upper respiratory, digestive health, pain and sleep, and healthy lifestyle products worldwide |
| Specialty Care | Operating Segment | Global women's health and skin health unit spanning contraceptives, scar care and skin healing |
| Infant Formula | Operating Segment | Store brand and branded infant nutrition unit placed under formal strategic review in 2026 |
| Opill | Brand | First daily oral contraceptive cleared for over the counter sale in the United States |
| ellaOne | Brand | European emergency contraceptive brand that joined Perrigo through the HRA Pharma purchase |
| Mederma | Brand | Scar care and skin healing line sold in the United States and selected international markets |
| Compeed | Brand | Blister, cold sore and foot care treatment brand distributed mainly across Europe |
| Solpadeine | Brand | Analgesic brand sold chiefly in the United Kingdom, Ireland and other European markets |
| Good Start | Brand | Branded infant formula line bought from Nestle together with a Wisconsin manufacturing plant |
| Ranir | Subsidiary | Grand Rapids, Michigan based private label oral self care supplier bought in 2019 |
| HRA Pharma | Subsidiary | Paris based consumer self care business bought in 2022 and now the core of Specialty Care |
| Allegan Michigan Campus | Manufacturing Facility | Original and largest United States production and research site for store brand over the counter medicines |
Portfolio Analysis
Most of what Perrigo makes reaches shoppers under another company's name, and that is the point of the business rather than a failure to market it. From the first quarter of 2026 the company reports four groupings in place of the two geographic segments it used through fiscal 2025, and we read the change as preparation to sell pieces rather than a tidying of disclosure. Self Care covers upper respiratory, digestive health, pain and sleep, and healthy lifestyle products worldwide. It produced $576.6 million of net sales in the quarter ended June 27, 2026 and $1,119.9 million in the half. Specialty Care holds women's health and skin health, and it added $226.6 million in the quarter and $433.6 million so far this year. Infant Formula contributed $100.9 million, up 23.1% from a year earlier. All Other, which carries Oral Care and leftover lines, delivered $118.6 million. First-half net sales came to $1,992.0 million. The branded part of the portfolio is small, and we think it earns most of the profit. Opill is the first daily oral contraceptive cleared for sale without a prescription in the United States, and ellaOne sells in Europe. Mederma treats scars and Compeed treats blisters. Solpadeine and Coldrex sell as painkillers and cold remedies in Europe, NiQuitin helps people quit smoking and Jungle Formula repels insects. Plackers, REACH and Rembrandt came with the Ranir oral care business bought in 2019, and Good Start carries branded infant nutrition. What we like is the double route to the shelf. Few rivals can compete in a category both as the retailer's supplier and as a brand owner. Our concern is that the bigger half of that is not Perrigo's to decide. Retailers set the price of their own store brands. Fiscal 2025 showed the cost, as Consumer Self-Care Americas net sales fell 4.0% to $2.59 billion on weaker shopper demand and thinner contract manufacturing work. Opill and ellaOne did not make up the difference, and we do not expect two brands that size to make up a weak store brand year in 2026 either.
Market Share & Competitors
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Perrigo Company plc ★ | N/A | $4.25B (FY2025) | Irish domiciled maker of store brand and branded over the counter self-care products and infant formula |
| Kenvue Inc. | N/A | $15.12B (FY2025) | Consumer health group spun out of Johnson & Johnson, owner of Tylenol, Band-Aid and Listerine |
| Reckitt Benckiser Group plc | N/A | $18.32B (FY2025) | United Kingdom consumer health and hygiene group behind Mucinex, Nurofen and Enfamil |
| Haleon plc | N/A | $14.23B (FY2025) | United Kingdom consumer health company formed from the GSK and Pfizer joint venture, owner of Advil and Centrum |
| Viatris Inc. | N/A | $14.30B (FY2025) | Global generics and established medicines maker with a sizable over the counter portfolio |
| Prestige Consumer Healthcare Inc. | N/A | $1.09B (FY2026) | United States marketer of niche over the counter brands including Clear Eyes and Dramamine |
Competitive Analysis
Perrigo sells a fraction of what its branded rivals sell. Kenvue Inc. recorded $15.12 billion of net sales in 2025 and Reckitt Benckiser Group plc recorded 14.20 billion pounds, the equivalent of $18.32 billion, against Perrigo's $4.25 billion. Haleon plc reported 11.03 billion pounds, a little over $14.23 billion, with 3.0% organic growth and 10.5% organic operating profit growth, and Viatris Inc. reported $14.30 billion. Perrigo's revenue fell 2.8% in fiscal 2025 and organic sales fell 2.4%. We do not think the size gap is the main story, because Perrigo is not trying to outspend anyone. The branded companies sell familiar names such as Tylenol, Advil, Mucinex and Centrum, and they protect those names with advertising budgets a $4.25 billion manufacturer cannot match. Perrigo instead makes the store brand that sits next to those products on the same shelf at a lower price, so every shopper who switches to the cheaper option sends volume its way. Management reported gains in store brand share through 2025 even as categories weakened, and we take that as the best evidence the approach still works. Our caution is about how much money the approach makes. Prestige Consumer Healthcare Inc. is the closest comparison, with $1.09 billion of revenue in the year to March 31, 2026, a quarter of Perrigo's sales. Investors value Prestige at a far higher multiple of its sales than Perrigo's $1.98 billion market value implies, and we think Prestige deserves that premium. It owns small brands of its own, so it sets its own prices and pays someone else to do the manufacturing. Perrigo owns the factories, absorbs raw material costs and sells to a handful of large retailers that negotiate hard. Infant formula is the clearest version of the problem, because Abbott Nutrition and Reckitt's Enfamil franchise set branded prices while Perrigo carries the fixed costs of its plants. With 2026 adjusted earnings per share guidance held at $2.00 to $2.30, we see very little room for another drop in demand before the investment case has to be rewritten.
Acquisitions
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Agis Industries | $818.0M | 2005 | Israeli generic pharmaceutical and consumer products maker that gave Perrigo its first large international manufacturing base. |
| PBM Holdings | $808.0M | 2010 | Store brand infant formula producer that made Perrigo the leading United States private label infant nutrition supplier. |
| Paddock Laboratories | $540.0M | 2011 | Minneapolis based generic prescription drug maker folded into the former Rx segment. |
| Elan Corporation plc | $8.60B | 2013 | Irish biotechnology company acquired in a reverse merger that moved Perrigo's legal domicile to Dublin. |
| Omega Pharma | $4.50B | 2015 | Belgian over the counter self care company, bought for 3.6 billion euros, that created a top five global OTC platform. |
| Ranir Global Holdings | $750.0M | 2019 | Private label oral self care supplier of toothbrushes, whitening strips and flossers based in Michigan. |
| HRA Pharma | $2.10B | 2022 | Paris based consumer self care company bought for 1.8 billion euros, bringing ellaOne, Compeed and the Opill program. |
| Nestle Gateway Infant Formula Assets | N/A | 2023 | Eau Claire, Wisconsin infant formula plant and the Good Start brand purchased from Nestle. |
Acquisitions Analysis
Three deals account for most of the balance sheet Perrigo is now taking apart. They are Elan Corporation plc at $8.60 billion in 2013, Omega Pharma at $4.50 billion completed March 30, 2015 and HRA Pharma at $2.10 billion completed May 2, 2022. We rate the earlier purchases far higher. Agis Industries of Israel at $818.0 million in 2005 built the first manufacturing network outside the United States. PBM Holdings at $808.0 million in 2010 made Perrigo the leading American supplier of store brand infant formula. Paddock Laboratories at $540.0 million in 2011 added to a prescription business later sold whole. Ranir Global Holdings at $750.0 million in 2019 opened oral care, and the 2023 purchase of Nestle's Eau Claire, Wisconsin plant and the Good Start brand added branded formula capacity just as United States supply ran short. The case for all this buying is real and we grant it. Acquisitions turned a single-country store brand supplier into a self-care company selling in 31 countries with 8,100 employees, and HRA brought the two products now carrying growth, ellaOne and Opill. We think the writedowns outweigh that, because they land on the same assets. Perrigo wrote off $1.3 billion of goodwill in fiscal 2025 and another $331.8 million in the first half of 2026 against Infant Formula, Women's Health and Oral Care, which came from PBM, HRA and Ranir respectively. That is not chance. It is what paying full prices for growth costs when store brand demand weakens. Money that went in at a premium is coming back at a discount. Dermacosmetics, built largely out of Omega, was sold on April 30, 2026 for $362.9 million of net proceeds, and HRA Pharma Rare Diseases went to Esteve in 2024 for up to 275 million euros. Interim chief executive Albert Manzone now has Infant Formula and Oral Care under strategic review, and Perrigo bought both rather than building them. Before we credit this management with buying well, we would want two straight years of growth from the businesses it keeps.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
December 2013 still sets the terms for this company, and we think it brought Perrigo as much harm as benefit. Paying $8.60 billion for Elan Corporation plc delivered an Irish domicile, a lower tax rate and the Tysabri royalty stream, which Perrigo sold to Royalty Pharma in 2017 for $2.20 billion plus later payments. It also made Perrigo a target. Within eighteen months Mylan was pursuing an unsolicited offer to swap its own shares for Perrigo's, and shareholders turned it down in November 2015, persuaded by the promise of the Omega Pharma integration. Joseph Papa left for Bausch Health in 2016, and the shares have never again reached the price at which that offer was refused. The defence succeeded and shareholders lost money anyway. Everything since has been subtraction. The July 2021 sale of the prescription pharmaceuticals and diagnostics business to Altaris Capital Partners for $1.55 billion made Perrigo a pure consumer self-care company. Perrigo kept the liabilities that arose before the closing, with Altaris covering 50% of them up to a $50.0 million cap, an obligation still disclosed in 2026 filings. HRA Pharma Rare Diseases went to Esteve in 2024 for up to 275 million euros, and Dermacosmetics closed on April 30, 2026 for $362.9 million of net proceeds. The pattern is not a flattering one. Perrigo is selling off, at prices the buyers set, the spread of businesses it once paid premiums to assemble. The fair counter-argument is that each sale removes complexity and funds debt reduction toward the stated 4.0 times target, and we accept that a simpler Perrigo is easier to value and easier to run. We doubt that is enough. With the shares near $14.26, five analysts targeting $16.50 and takeover talk returning through 2026, we think investors are betting on one more deal in this chain, and that the asset for sale is Perrigo itself.
Ownership History
Ownership History Analysis
Perrigo stopped being a family company three decades before it stopped being an American one. Luther and Charles Perrigo opened a general store in Allegan, Michigan in 1887 that packaged and sold home remedies. They incorporated the business in 1892, and the family held it for roughly ninety years, with five of the first seven presidents descended from the founder. Management bought the company in the early 1980s. Grow Group acquired it in 1986 for $45.0 million, and management bought it back in 1988 for $106.0 million. The 1991 Nasdaq initial public offering under the ticker PRGO put it in public hands permanently. The listing moved to the New York Stock Exchange when the Elan reverse merger created Perrigo Company plc in 2013. What we follow across that history is a shareholder base that grew steadily more institutional and steadily less committed. BlackRock at 16.40%, Neuberger Berman Investment Advisers at 7.70%, Vanguard Group at 6.52% and State Street Investment Management at 6.15% now hold the place a founding family once held, and individual insiders own under 0.5%. Two moments show what that is worth. Shareholders voting their own shares kept Perrigo independent by refusing Mylan in November 2015. The board, with no controlling owner to consult, replaced Patrick Lockwood-Taylor with interim chief executive Albert Manzone in June 2026, within days of a finding about his conduct. We judge both outcomes faster and cleaner than a controlled company would have managed, and on governance alone we would keep these shareholders over a family block. The cost of having no anchor investor shows up elsewhere, and Perrigo is paying it now. A $1.98 billion market value carries $3,283.4 million of noncurrent long-term debt. The dividend yield of 8.14% tells us investors do not believe the payout. And no big shareholder is committed to funding a recovery that takes years. That, we think, is why takeover talk returns every time the shares fall.
Ownership Explained
Perrigo Company plc has no controlling owner. Its ordinary shares trade on the New York Stock Exchange under PRGO, and with 138.8 million shares outstanding as of June 27, 2026 the register is held almost entirely by professional money managers; third party ownership tabulations put institutional holdings near 99% of the float and individual insiders below 0.5%. BlackRock is the single largest holder at roughly 16.40%, a position it disclosed again in a September 2026 regulatory filing. Neuberger Berman Investment Advisers follows at 7.70%, with Vanguard Group at 6.52% and State Street Investment Management at 6.15%. The Perrigo family, which controlled the business from its 1887 founding in Allegan, Michigan until a management buyout in the early 1980s, no longer holds a stake of record. Governance sits with an independent board chaired by Orlando D. Ashford; Albert Manzone has served as interim president and chief executive since June 2026, when Patrick Lockwood-Taylor resigned.
Because Perrigo is owned by diversified index and value managers rather than a family or a sponsor, strategy is set by the board and management and tested each year by a one share, one vote shareholder meeting. That structure has mattered twice in visible ways. In November 2015 shareholders, not a founder, decided Perrigo's fate when they declined Mylan's unsolicited exchange offer. In June 2026 the board removed a sitting chief executive over conduct findings without needing a controlling holder's consent. For consumers the practical effect is limited: the same Allegan, Michigan and European plants make store brand medicines for retailers whose own labels appear on the box, so shoppers buying a retailer brand pain reliever or infant formula are often buying a Perrigo product without seeing the name. For investors the effect is that a $1.98 billion market value sits against roughly $3.3 billion of long-term debt, which makes divestiture proceeds and leverage reduction the lever that ownership pressure pulls hardest.